Trump's DOJ Moves Medical Marijuana to Schedule III: What It Means

The Order That Changed Federal Cannabis Law

On April 23, 2026, the acting attorney general signed an order that cannabis advocates had been waiting decades to see. State-licensed medical marijuana was officially reclassified from Schedule I — the category reserved for drugs deemed to have no accepted medical use and a high potential for abuse — to Schedule III, placing it alongside ketamine, anabolic steroids, and certain codeine formulations.

The shift did not come out of thin air. President Trump's December 2025 executive order on rescheduling set the machinery in motion, and the Drug Enforcement Administration had been reviewing the scientific and medical evidence throughout early 2026. But the April 23 order was the moment the bureaucratic gears actually turned, and the implications are immediate and far-reaching.

What Schedule III Actually Means

To understand the significance, you need to understand what Schedule I meant. Under that classification, the federal government's official position was that marijuana had "no currently accepted medical use" — a stance that became increasingly absurd as 40 states built out regulated medical programs serving millions of patients.

Schedule III recognition flips that posture. The federal government now acknowledges that state-licensed medical cannabis has legitimate therapeutic applications. That single sentence carries enormous downstream consequences.

Tax Relief Under Section 280E

The most immediate financial impact lands on cannabis operators' balance sheets. Under IRS Code Section 280E, businesses trafficking in Schedule I or II substances cannot deduct standard business expenses — rent, payroll, marketing, utilities — from their federal taxes. This created effective tax rates between 60 and 80 percent for many cannabis companies, a burden that has driven countless operators into insolvency.

With medical marijuana now at Schedule III, licensed medical operators can deduct those expenses like any other business. Industry analysts estimate this will save the sector billions of dollars annually and immediately push many companies from loss to profitability.

Research Barriers Fall

Schedule I classification required researchers to navigate a labyrinthine approval process to study cannabis, including obtaining a special DEA license and sourcing material exclusively from the University of Mississippi's federally authorized grow operation — material that researchers widely regarded as unrepresentative of what patients actually consumed.

Schedule III dramatically lowers those barriers. Researchers can now work with cannabis that reflects real-world products, and the approval timeline shrinks from years to months. The National Institutes of Health and university research programs are already expanding their cannabis study portfolios in response.

Banking Pathways Open

While the rescheduling does not fully resolve cannabis banking — marijuana remains federally controlled, and recreational cannabis is still Schedule I — it opens new pathways for financial institutions serving medical operators. Several regional banks and credit unions have already signaled they will expand cannabis-related services in the wake of the order.

What the Order Does Not Do

It is equally important to understand the limits of the April 23 action.

Recreational marijuana remains Schedule I. The order applies specifically to state-licensed medical cannabis and FDA-approved cannabis drug products. If you operate a recreational dispensary in Colorado or California, your federal tax situation has not changed — yet.

Full legalization is not on the table. Schedule III is not the same as descheduling. Cannabis remains a controlled substance, subject to federal regulation and enforcement. The DEA still has jurisdiction, and interstate commerce in cannabis is still prohibited.

The broader rescheduling process is ongoing. The DOJ announced that it is "jump-starting" the process for reclassifying marijuana more broadly, with an evidentiary hearing set to begin on June 29, 2026. That hearing will consider whether all marijuana — including adult-use — should move to Schedule III. A final rule is possible before the end of the year, but not guaranteed.

Industry Reaction

The cannabis industry's response was swift and overwhelmingly positive, though tempered with pragmatism.

Multi-state operators like Curaleaf, Green Thumb Industries, and Trulieve saw their stock prices surge in the days following the announcement. Penny stocks like Akanda Corp experienced even more dramatic spikes, with shares jumping over 200 percent in a single session before partially retracing.

Industry trade groups called the move "a generational milestone" while emphasizing that the work is not done. The National Cannabis Industry Association noted that recreational operators still face the 280E burden, and that comprehensive reform — including the SAFE Banking Act or full descheduling — remains the ultimate goal.

What Comes Next

The June 29 Hearing

The evidentiary hearing on broader rescheduling is the next major milestone. If the DEA determines that the scientific and medical evidence supports moving all marijuana to Schedule III, it could issue a proposed rule as early as late summer, with a final rule potentially landing before year-end.

State-Level Dynamics

The federal shift is landing amid a complex state-level landscape. Nine states have filed cannabis reform measures for the November 2026 ballot. But there is also a countermovement: Arizona is collecting signatures for a repeal initiative, and Massachusetts has a proposed ballot measure that would roll back its recreational program while preserving medical access.

Banking Legislation

Congressional supporters of the SAFE Banking Act are using the rescheduling momentum to push for a standalone banking bill. While the legislation has failed multiple times, advocates argue that the political calculus has shifted now that the executive branch has acknowledged marijuana's medical legitimacy.

The Bottom Line

The April 23 order is the most significant federal cannabis policy change since the Controlled Substances Act was enacted in 1970. It does not legalize marijuana, and it does not solve every problem facing the industry. But it acknowledges a reality that 40 states and tens of millions of Americans have recognized for years: cannabis has medical value, and treating it like heroin was always bad policy.

The next six months will determine whether this was a first step or a half-measure. The June hearing, the November ballot measures, and the banking debate will all shape the trajectory. But for the first time in the modern cannabis era, the federal government is moving in the same direction as the states — and that is a development worth paying attention to.

As federal policy catches up to state-level access, find a dispensary near you to explore what medical and adult-use programs are available in your state right now.